Recently, soluble PD-L1 (sPD-L1) within the plasma or serum has been identified as a prognostic marker in different cancer types, such as prostate cancer [9], melanoma [10], renal cell carcinoma [11], glioma [12], and non-small cell lung cancer (NSCLC) [13]. This evidence concerns the gene SPDL1 and cancer.